Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2019-04-16

FDA Approved: ENTECAVIR — Supplemental Application (AvKARE)

View source ↗

Summary

FDA approved a supplemental application for AvKARE to market entecavir, a hepatitis B antiviral, creating availability of a generic version. This action updates…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ENTECAVIR (ENTECAVIR)

Snippet

SUPPL AP for ENTECAVIR (ENTECAVIR)